Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 13/20 | 0.73 |
| ▸ | GRIK2 | Q13002 | 12/20 | 0.73 |
| ▸ | HTR2A | P28223 | 3/20 | 0.59 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.56 |
| ▸ | PAM | P19021 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL504608 | 1.00 | GRIK1 (0.73) | GRIK1GRIK2HTR2AGRIK3PAM | |
| SCHEMBL1865552 | 1.00 | GRIK1 (0.73) | GRIK1GRIK2HTR2AGRIK3PAM | |
| SCHEMBL3579939 | 1.00 | GRIK1 (0.73) | GRIK1GRIK2HTR2AGRIK3PAM | |
| SCHEMBL3579937 | 1.00 | GRIK1 (0.73) | GRIK1GRIK2HTR2AGRIK3PAM | |
| SCHEMBL1865554 | 1.00 | GRIK1 (0.73) | GRIK1GRIK2HTR2AGRIK3PAM | |
| SCHEMBL594002 | 0.85 | GRIK1 (1.00) | GRIK1GRIK2GRIK3 | |
| SCHEMBL594001 | 0.85 | GRIK1 (1.00) | GRIK1GRIK2GRIK3 | |
| SCHEMBL594000 | 0.85 | GRIK1 (1.00) | GRIK1GRIK2GRIK3 | |
| SCHEMBL593999 | 0.85 | GRIK1 (1.00) | GRIK1GRIK2GRIK3 | |
| SCHEMBL2354701 | 0.84 | GRIK1 (0.55) | GRIK1GRIK2GRIK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534498-B2 | Compounds for use as apelin receptor antagonists | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2026-01-27 | — | — | US | disclosed |
| US-20240279280-A1 | COMPOUNDS FOR USE AS APELIN RECEPTOR ANTAGONISTS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-08-22 | — | — | US | disclosed |
| US-20240200049-A1 | COMPOSITIONS AND METHODS OF USE THEREOF FOR MAKING POLYPEPTIDES WITH MANY INSTANCES OF NONSTANDARD AMINO ACIDS | YALE UNIVERSITY | 2024-06-20 | — | — | US | disclosed |
| US-11976137-B2 | Compounds for use as apelin receptor antagonists | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-05-07 | — | — | US | disclosed |
| US-11976137-B2 | Compounds for use as apelin receptor antagonists | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-05-07 | — | — | US | disclosed |
| US-11976137-B2 | Compounds for use as apelin receptor antagonists | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-05-07 | — | — | US | disclosed |
| US-11702652-B2 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION A/S (DK) | 2023-07-18 | — | — | US | disclosed |
| US-11702652-B2 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION A/S (DK) | 2023-07-18 | — | — | US | disclosed |
| US-11649446-B2 | Compositions and methods of use thereof for making polypeptides with many instances of nonstandard amino acids | YALE UNIVERSITY (US) | 2023-05-16 | — | — | US | disclosed |
| US-11408007-B2 | Compositions and methods for biocontainment of microorganisms | YALE UNIVERSITY (US) | 2022-08-09 | — | — | US | disclosed |
| US-20100286036-A1 | NOVEL PEPTIDES THAT ENHANCE TIGHT JUNCTION PERMEABILITY | Alba Therapeutics, Inc. (US) | 2010-11-11 | — | — | US | disclosed |
| WO-2009137436-A2 | PEPTIDE CONJUGATES | ALBA THERAPEUTICS CORPORATION (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090264300-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION A/S (DK) | 2009-10-22 | — | — | US | disclosed |
| US-20090264300-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION A/S (DK) | 2009-10-22 | — | — | US | disclosed |
| WO-2009015382-A2 | NOVEL PEPTIDES THAT ENHANCE TIGHT JUNCTION PERMEABILITY | ALBA THERAPEUTICS CORPORATION (US) | 2009-01-29 | — | — | WO | disclosed |
| WO-2007062664-A2 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION A/S (DK) | 2007-06-07 | — | — | WO | disclosed |
| WO-2004084842-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2004-10-07 | — | — | WO | disclosed |
| US-5629293-A | Single chain peptide compounds having hemoregulatory activity | NYCOMED IMAGING AS (NO) | 1997-05-13 | — | — | US | disclosed |
| EP-0643725-A1 | SINGLE CHAIN PEPTIDE COMPOUNDS HAVING HEMOREGULATORY ACTIVITY | NYCOMED IMAGING AS (NO) | 1995-03-22 | — | — | EP | disclosed |
| WO-1993024524-A1 | SINGLE CHAIN PEPTIDE COMPOUNDS HAVING HEMOREGULATORY ACTIVITY | HAFSLUND NYCOMED AS (NO) | 1993-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264300-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | RNGTT, DUT, EMG1 | GRIK1 3497/4885GRIK2 3660/4885HTR2A 4470/4885 |
| US-12534498-B2 | Compounds for use as apelin receptor antagonists | APLNR, NPBWR1, AP3B1 | GRIK1 940/4885GRIK2 1547/4885HTR2A 169/4885 |
| US-20100286036-A1 | NOVEL PEPTIDES THAT ENHANCE TIGHT JUNCTION PERMEABILITY | VIP, FABP2, GJA1 | GRIK1 1662/4885GRIK2 1840/4885HTR2A 3311/4885 |
| US-11976137-B2 | Compounds for use as apelin receptor antagonists | APLNR, GIPR, GRPR | GRIK1 531/4885GRIK2 719/4885HTR2A 752/4885 |
| US-20240279280-A1 | COMPOUNDS FOR USE AS APELIN RECEPTOR ANTAGONISTS | APLNR, GIPR, GRPR | GRIK1 531/4885GRIK2 719/4885HTR2A 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.